

# Bromolac™

Bromocriptine

**Active Ingredient**  
Bromocriptine.

## Indication

Dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Prolactin-secreting adenomas, Acromegaly, Parkinson's Disease.

## Dosage & Administration

**General:** It is recommended that Bromocriptine mesilate be taken with food. Patients should be evaluated frequently during dose escalation to determine the lowest dosage that produces a therapeutic response.

**Hyperprolactinemic Indications:** The initial dosage is 1.25 mg to 2.5 mg tablet daily. An additional 2.5 mg tablet may be added to the treatment regimen as tolerated every 2-7 days until an optimal therapeutic response is achieved. **Acromegaly:** The initial recommended dosage is 1.25 to 2.5 mg on retiring (with food) for 3 days. An additional 1.25 to 2.5 mg should be added to the treatment regimen as tolerated every 3-7 days until patient obtains optimal therapeutic benefit. **Parkinson's Disease:** The initial dose of Bromocriptine mesilate is 1.25 mg of a 2.5 mg tablet twice daily with meals.

**Prolactinomas:** 2.5 mg to 3.75 mg daily

**Inhibition of lactation:** 5 mg (1 tablet twice) daily with morning & evening meals for 14 days

## Contraindication & Precaution

Safety & efficacy of bromocriptine mesilate have not been established in patients with renal or hepatic disease. Care should be exercised when administering Bromocriptine therapy concomitantly with other medications known to lower blood pressure.

## Side Effect

The incidence of adverse effects are: nausea, headache, dizziness, fatigue, lightheadedness, vomiting, abdominal cramps, nasal congestion, constipation, diarrhea & drowsiness. A slight hypotensive effect may accompany treatment.

## Drug Interaction

Bromocriptine may interact with dopamine antagonists, butyrophenones, & certain other agents. Compounds in these categories result in a decreased efficacy of Bromocriptine: phenothiazines, haloperidol, metoclopramide, pimozide. Concomitant use of Bromocriptine with other ergot alkaloids is not recommended.

## Use in Pregnancy & Lactation

**Pregnancy Category B.**

**Nursing Mothers:** Bromocriptine should not be used during lactation in postpartum women.

## Use in Children

No data are available for bromocriptine use in pediatric patients under the age of 8 years.

## Preparation

2.5 mg Tablet.

Manufactured by



**SQUARE**  
PHARMACEUTICALS LTD.  
BANGLADESH